Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting

Opinion
Video

Ke Ning, MD, describes similarities and differences when implementing bispecific antibodies and CAR T-cell therapy for patients with relapsed or remitting multiple myeloma in the community oncology setting.

Related Videos
A panel of 4 experts on breast cancer
A panel of 4 experts on breast cancer
A panel of 4 experts
A panel of 4 experts
multiple myeloma clinical trial daratumumab/ Image Credits: © Dragana Gordic - stock.adobe.com
multiple myeloma clinical trial/Image Credits: © Studio Romantic - stock.adobe.com
Video 9 - "Unmet Needs in Relapsed or Refractory Multiple Myeloma"
Video 7 - "Role of Pharmacists in Operationalizing Bispecific Antibodies"
A panel of 3 experts on hepatic encephalopathy
A panel of 4 experts
© 2024 MJH Life Sciences

All rights reserved.